Results 121 to 130 of about 9,210,402 (249)

Quality in the analytical phase [PDF]

, 2010
In today's health care system the prevalence of medical errors seems to be high as stated by the report of the Institute of Medicine (IOM). An error rate of about 10% in clinical medical laboratories has been consistently reported in the literature. Most
Sonntag, Oswald
core   +1 more source

Hemolysis Index-based Estimated Redraw Risk and Cost Impact across Clinical Settings

Korean Journal of Clinical Laboratory Science
This study evaluated the hemolysis index (HI) distribution, estimated the redraw risk and associated cost across clinical settings using the publicly available de-identified ADLM/AACC 2023 Help with Hemolysis Data Challenge dataset.
Young-Hee LEE, Ho Keun CHOI, Hyun Ho SUNG   +2 more
doaj   +1 more source

Invisible but not inaccessible—Revealing transient oligomers formed by intrinsically disordered proteins with solution NMR and complementary methods

FEBS Letters, EarlyView.
Transient oligomers formed by intrinsically disordered proteins may be ‘invisible’ to direct detection yet remain accessible to solution NMR through equilibrium‐exchange measurements and pressure‐jump experiments. Complementary methods report on mass, stoichiometry, selected distance distributions, morphology, and internal packing.
Martin D. Gelenter, Ad Bax
wiley   +1 more source

Use of external quality assessment in extra-analytical phases in clinical laboratories in Spain: a survey by the Spanish Society of Laboratory Medicine (SEQCML)

Advances in Laboratory Medicine
Quality indicators (QIs) are a valuable tool for monitoring and improving extra-analytical phase performance in the clinical laboratory (CL). For that reason, the Spanish Society of Laboratory Medicine (SEQCML) launched its Pre-analytical Phase EQA ...
Caballero Garralda Andrea, Reixach Immaculada Comas, García Miralles Carlos, Gómez Rioja Rubén, Llopis Díaz María Antonia, Martínez Espartosa Débora, Nicolás de Blas Reyes, Panadès Turró Mariona, Puigví Fernández Laura, Rodelgo Jiménez Laura, Sufrate-Vergara Berta, Ventura Orriols Emma   +11 more
doaj   +1 more source

Going viral − Virus‐targeting nanobodies for research, diagnostics and therapy

FEBS Letters, EarlyView.
The increasing prevalence of viral diseases represents a major threat for global human health. Nanobodies, small binding fragments derived from camelid heavy‐chain antibodies, offer versatile tools for viral research, diagnostics, and antiviral therapy.
Domenic Ebert, Ulrich Rothbauer
wiley   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

Molecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska, Stephany Gallardo, Nur S. Zainal, Leena Arora, Matthew Ellis, Maria‐Antoinette Lopez, Judith Austine, Sai Pittla, Serena J Chee, Aiman Alzetani, Emily C Shaw, Christian H Ottensmeier, Gareth J Thomas, Christopher J Hanley   +13 more
wiley   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

Molecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura, Tadahiro Kuribayashi, Johannes Brägelmann, Sachi Okawa, Masataka Taoka, Shunta Mori, Tomoka Nishimura, Takaaki Tanaka, Go Makimoto, Kiichiro Ninomiya, Kammei Rai, Eiki Ichihara, Ryohei Katayama, Katsuyuki Hotta, Masahiro Tabata, Yosuke Togashi, Yoshinobu Maeda, Martin L. Sos, Katsuyuki Kiura, Kadoaki Ohashi   +19 more
wiley   +1 more source

Evaluation of different needle gauge blood collection sets (23G/25G) in aged patients

Journal of Laboratory Medicine
Aged patients are often characterized by difficult blood sampling conditions. Smaller needle gauge (G) may be beneficial for venous access and reduced pain perception, however, potentially at the expense of lower blood quality for laboratory measurements.
Rosada Adrian, Friedrich Katharina, Spieß Eileen, Prpic Monika, Müller-Werdan Ursula, Jahić Amir, Kappert Kai   +6 more
doaj   +1 more source

Finding novel vulnerabilities of hypomorphic BRCA1 alleles

Molecular Oncology, EarlyView.
Synthetic lethality screens performed to identify novel vulnerabilities often model complete gene loss, thereby overlooking patient‐derived hypomorphic mutations. In this study, we have performed genome‐wide CRISPR screens on BRCA1 hypomorphic mutations, showing BRCA1I26A behaves like wild‐type, while BRCA1R1699Q mimics deficiency. Furthermore, we have
Anne Schreuder, Klaas de Lint, Hồ Mỹ Phúc Võ, Mariana M. Góis, Rosalie A. Kampen, Marta San Martin Alonso, Ilse Nootenboom, Veronica Garzero, Tiemen J. Wendel, Rob M. F. Wolthuis, Sylvie M. Noordermeer   +10 more
wiley   +1 more source

Pre-analytical specimen labelling and processing errors in the ICU : Pre-analytical specimen processing errors in the ICU

, 2022
Introduction: Specimen rejections have been associated with increased in-hospital stay and cost. The majority of errors occur in the pre-analytic phase. Specimen rejection can lead to high rate of recollection, delay in result availability, and high rate
Nguyen, Long, Microys, Sherissa
core